Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility and Proof of Concept Studies

Inclusion Criteria: * Documented Type 1 or Type 2 Diabetes for at least 1 year prior to study enrolment * Aged ≥ 14 years * HbA1c of 6.5 ≤ A1c ≤ 10% * Using basal-bolus MDI therapy: 1. Basal insulin: Glargine, Degludec, or detemir and up to sum of 72 units of basal insulin 2. Bolus insulin: regular insulin, rapid analogues or ultra-rapid analogues * Subjects willing to follow study instructions: 1. For SMBG users (only for segment 1): measure capillary blood glucose at least 4 times a day . Document blood glucose level, insulin delivery, meals and daily activities. Wear CGM. 2. For CGM users (FGM with a reader or real-time CGM): Use CGM according to manufacture instructions, document insulin delivery, meals and daily activities. * Subjects using CGM or SMBG that are compatible with data transmission to the study diabetes management system (i.e. for CGM, FGM with a reader). * Fasting glucose target is \< = 180 mg/dl (T2D) * Subjects have home computer connected to the internet. * Subjects have a smart phone compatible with study requirements. * Subjects willing and able to sign a written informed consent form. Exclusion Criteria: * An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment. * Concomitant diseases/ treatment that influence metabolic control or any significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patients' safety * Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus, such as: * Subject has unstable or rapidly progressive renal disease or is receiving dialysis * Subject has active proliferative retinopathy * Active gastroparesis * Subject has loss of kidney function as measured by estimated Glomerular Filtration Rate (eGFR) \<45 in the previous 3 months 4. Participation in any other interventional study 5. Female subject who is pregnant or planning to become pregnant within the planned study duration * Subject is in the "honeymoon" phase - i.e. less than 0.5 insulin units/kg per day. * Drug or alcohol abuse.